Trial reportBMC cancer2025
Incidence and survival among children with neuroblastoma in Spain over 22 years.
Trial report in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01728155 (European Low and Intermediate Risk Neuroblastoma Protocol), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Low and Intermediate Risk Neuroblastoma Protocol
Who cites it
4 citing papers in PubMed.
- Robot-assisted versus conventional minimally invasive surgery in the treatment of paediatric neuroblastoma: a single-centre retrospective study.Pediatric surgery international · 2026Article
- Correction to: Incidence and survival among children with neuroblastoma in Spain over 22 years.BMC cancer · 2026Article
- Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroblastoma is the most common extracranial solid childhood tumour. Advances in risk stratification have improved survival by enabling better-tailored treatments. The Toronto Guidelines (TG) aim to standardise childhood cancer stage collection by cancer registries. However, population-based survival analyses by stage remain scarce. We aimed to study incidence and survival of neuroblastoma cases among Spanish children aged < 15 years, with special attention to the role of stage at diagnosis.
methodsThe Spanish Registry of Childhood Tumours (RETI-SEHOP) and the Spanish Neuroblastoma Clinical Database (NBL-CDB) were cross-linked to achieve nearly complete registration of neuroblastoma in Spain for the period of diagnosis 2000–2021. Kaplan-Meier estimates were obtained for overall survival (OS). Adjusted survival was estimated using a Cox proportional hazards model with stratification by age group.
resultsDuring 2000–2021, 1774 neuroblastoma cases aged 0–14 years were recorded, making a rough average of 81 cases diagnosed annually. Age-standardised incidence rate (World) 2000–2021: 14.0 cases per million children (0–14 years). Distribution of stage at diagnosis remained stable from 2000 to 2021. 5-year OS increased from 74% (2000–2005) to 81% (2012–2017). Statistically significant OS differences were identified between sexes, age groups, tumour morphologies, primary sites and stages. Over time, survival improvement was centred mostly on male and locoregional cases.
conclusionsNeuroblastoma incidence and survival results in Spain were consistent with those from other high-income countries. Survival improvements were related to changes in clinical management, such as administration of anti-GD2 immunotherapy or the start of the LINES clinical trial (EudraCT 2010-021396-81, registered on 15 June 2011; ClinicalTrials.gov identifier: NCT01728155). This study underscores the clinical interest in stage data being collected by cancer registries, as per the TG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.